Cessatech A/S (FRA:8GN)

Market Cap	23.12M -13.7%
Revenue (ttm)	432.30K -35.0%
Net Income	-1.31M
EPS	-0.07
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,000
Open	1.025
Previous Close	1.110
Day's Range	1.025 - 1.045
52-Week Range	0.650 - 3.345
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Cessatech

Cessatech A/S, a pivotal-stage pediatric biotech company, develops specialty hospital medicines for children in Denmark. Its lead candidate product is CT001, a fixed-dose nasal spray for treating acute pain in children. The company also develops CT002, a non-invasive intranasal sedation for children undergoing medical procedures in Phase 2 clinical trials; and CT003, a topical anesthetic in pre-clinical development. The company has a collaboration with University Hospital of Copenhagen, Rigshospitalet, to advance an intravenous formulation of m...

• Industry: Pharmaceutical Preparations
• Founded: 2020
• Employees: 3
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8GN

Financial Performance

In 2025, Cessatech's revenue was 5.72 million, an increase of 130.01% compared to the previous year's 2.49 million. Losses were -10.90 million, -25.67% less than in 2024.

Financial numbers in DKK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error